Prostate-specific antigen decline during salvage radiation therapy following prostatectomy is associated with reduced biochemical failure

Prostate-specific antigen decline during SRT may be a valuable prognostic factor for subsequent clinical outcomes. Future studies should investigate the value of monitoring PSA during SRT and how PSA response may be used to personalize therapy.